Xiaohuan Zhang

Dr. Xiaohuan Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JXJunhong Xu
Junhong Xu
YYYouhua Yuan
Youhua Yuan
GCGuohua Chen
Guohua Chen
BMBing Ma
Bing Ma
YZYin Long Zou
Yin Long Zou
XZXiaohuan Zhang
Xiaohuan Zhang
Introduction: The long-term immunogenicity, adverse effects, influencing factors, and protection from booster vaccines remain unclear. Specifically, little is known regarding the humoral immunity and breakthrough infections associated with COVID-19 booster immunization. Therefore, we evaluated the immunogenicity, reactogenicity, influencing factors, and protective effects of the first coronavirus disease booster vaccine 23 months before and after implementation of dynamic zero epidemic control measures among healthcare staff.Methods: We prospectively included 389 healthcare staff members in China with negative pre-enrolment severe acute respiratory syndrome coronavirus 2 test results. Neutralising serum antibodies were evaluated every two months till 23 months post-booster vaccination. Breakthrough infection was recorded or confirmed by SARS-CoV-2 specific PCR testing via throat swabs from participants before and after dynamic zero epidemic control measures.Results: At 15–30 days after vaccination, the mean concentration of the booster vaccine was 6.4 times above initial concentrations. Poorer antibody responses by booster vaccine correlated with male sex, longer post-booster duration, same-manufacturer vaccines, post-routine epidemic control measures implementation and intervals >210 days between primary and booster vaccinations. Higher breakthrough rates were associated with longer post-booster durations and post-routine epidemic control measures implementation but not associated with levels of neutralising antibodies after booster vaccination from participants. Adverse reactions were non-serious. These booster vaccine doses induced rapid, robust antibody responses, maintained for only 6–7 months.Discussion: Neutralizing antibodies induced by breakthrough infection with SARS-CoV-2 were weaker than those induced by the first COVID-19 booster vaccine, predicting that antibodies induced by SARS-CoV-2 may be very different from those of other known infectious pathogens.

30 August 2024 in Medicine
Verified
Journal Article
Open access
YYYou hua Yuan
You hua Yuan
WTWenqian Tian
Wenqian Tian
XWXiaoxia Wei
Xiaoxia Wei
YZYa Zhu
Ya Zhu
FLFengzhen Liu
Fengzhen Liu
XZXiaohuan Zhang
Xiaohuan Zhang
The use of 3 biomarkers – cystatin-C (Cys-C), retinol-binding protein (RBP), and ischemia-modified albumin (IMA) – for the clinical classification and outcome of coronary heart disease (CHD) has not been adequately evaluated. We explored the serum levels of these 3 markers and evaluated their diagnostic and prognostic values in patients with CHD. This retrospective case–control study, conducted between June 2017 and June 2018, included 201 patients with CHD hospitalized at the Henan Provincial People’s Hospital and 127 healthy individuals from Henan Provincial People’s Hospital as controls. Cys-C, RBP, IMA levels, and other laboratory parameters in the 2 groups were determined, and patient outcomes were analyzed. Cys-C, RBP, and IMA levels were higher in the case group than in the control group (P < .05). Logistic regression analysis confirmed that these 3 biomarkers were independent risk factors for CHD. Each indicator has clinical significance in the diagnosis and prognosis of CHD, with RBP being the most significant. The AUC value for CHD detection using a combination of the 3 indicators was 0.783, and the sensitivity and specificity values were 78% and 74.6%, respectively. Simultaneous detection of Cys-C, RBP, and IMA could be an optimal method for early diagnosis and prognosis of CHD.

18 July 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
XZXiaohuan Zhang
Xiaohuan Zhang
To elucidate the correlation between immunoglobulin G (IgG) N-glycosylation patterns (IGPs) and diabetes complications, including diabetic nephropathy (DN), diabetic retinopathy (DR) and diabetic maculopathy (DM). We performed a two-sample Mendelian randomization (MR) study. We obtained genome-wide association studies (GWAS) summary statistics related to 77 IGPs and diabetic complications from the MRC Human Genetics Unit and the FinnGen consortium. In our two-sample MR, genetic variants associated with IGPs were used to estimate correlations. The inverse-variance weighted (IVW) method was used as the primary analysis. Various complementary methods, including MR-Egger, weighted median (WM), and weighted mode were implemented to detect the causal relationship. Sensitivity analyses including MR-PRESSO, MR-Egger, Cochran's Q and leave-one-out methods were used to validate the robustness of the results. After MR-PRESSO outlier correction and a stringent False Discovery Rate (FDR) correction, a significant causal association was identified: higher levels of IGP48 were robustly associated with an increased risk of diabetic maculopathy (DM) (OR: 1.21, 95% CI: 1.09-1.35, P = 0.001, FDR = 0.004). Additionally, several other nominal associations (P < 0.05) were observed that did not withstand FDR correction but suggest areas for future investigation. These included protective associations with DM for IGP18 (OR: 0.86, P = 0.033) and IGP35 (OR: 0.90, P = 0.015), and risk associations for IGP23 (OR: 1.19, P = 0.028) and IGP28 (OR: 1.17, P = 0.038). For diabetic retinopathy (DR), a nominal protective association was found for IGP35 (OR: 0.94, P = 0.026) and a risk association for IGP48 (OR: 1.07, P = 0.042). Sensitivity analyses detected no significant horizontal pleiotropy, and the results were stable. Our study provides robust genetic evidence identifying IGP48 as a causal risk factor for DM. Other nominal associations with DM and DR require further validation. IGP48 emerges as a promising biomarker and therapeutic target for DM, warranting further research into its underlying mechanisms and clinical utility. Not applicable.

22 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YYYou hua Yuan
You hua Yuan
XJXu Junhong
Xu Junhong
GCGuohua Chen
Guohua Chen
LOLibo Ouyang
Libo Ouyang
YLYan Liu
Yan Liu
RWRong Wang
Rong Wang
The neutralisation ability of homologous and heterologous booster vaccinations against the KP.2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We evaluated Omicron variants (XBB.1, JN.1, and KP.2) neutralisation in participants vaccinated with heterologous versus homologous boosters. In 38 participants each from homologous and heter-ologous booster groups over 690 days, serum pseudovirus neutralisation was tested against the prototype, XBB.1, JN.1, and KP.2 variants to detect neutralisation titres. Total concentration of neutralising antibodies against SARS-CoV-2 receptor-binding domain was measured by en-zyme-linked immunosorbent assay. On throat swab samples, reverse transcription polymerase chain reaction was used to verify breakthrough SARS-CoV-2 infections in participants. Geometric mean neutralising titres against the prototype, total, XBB.1, JN.1, and KP.2 variants were 488.3, 54.5, 42.9, 39.7, and 39.8, respectively. Neutralisation assays revealed 12.3-, 12.3-, and 11.4-fold reduc-tions against JN.1, KP.2, and XBB.1 variants, respectively, compared with the prototype. No sig-nificant difference occurred in neutralising antibody titres among JN.1, KP.2, and XBB.1 Omicron variants. Homologous booster group and males produced fewer neutralising antibodies than heterologous booster group and females, respectively. KP.2 Omicron variant exhibited compa-rable immune evasion properties with other variants. A second different-type or broad-spectrum booster may improve neutralisation against Omicron variants KP.2.